Literature DB >> 26171007

Acute thrombocytopenia: An uncommon complication occurring following transarterial chemoembolization in a patient with neuroendocrine hepatic metastases.

Pingkun Xie1, Zheng Yuan2.   

Abstract

Neuroendocrine tumors are a group of carcinomas that secrete various polypeptides with hormonal activity. A significant percentage of patients already have hepatic metastases at the time of initial diagnosis, and 80-90% of these tumors are inoperable at the time of presentation. Transarterial chemoembolization (TACE) is the preferred approach for the management of neuroendocrine hepatic metastases. Although the technique is relatively safe, it is associated with several complications. The present study reported the case of a patient with neuroendocrine hepatic metastases who developed acute thrombocytopenia following TACE. To the best of our knowledge, acute thrombocytopenia occurring after TACE in a patient with neuroendocrine hepatic metastases has not been previously reported. In the present study, the hypothetical etiopathogenetic mechanisms were also discussed.

Entities:  

Keywords:  liver; metastases; neuroendocrine; transarterial chemoembolization

Year:  2015        PMID: 26171007      PMCID: PMC4487171          DOI: 10.3892/ol.2015.3232

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

Review 1.  Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature.

Authors:  Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  Immune-mediated platelet destruction and thrombocytopenia in patients with solid tumours.

Authors:  K A Schwartz; S J Slichter; L A Harker
Journal:  Br J Haematol       Date:  1982-05       Impact factor: 6.998

3.  Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization.

Authors:  C Proye
Journal:  World J Surg       Date:  2001-06       Impact factor: 3.352

4.  Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results.

Authors:  Christian Loewe; Martin Schindl; Manfred Cejna; Bruno Niederle; Johannes Lammer; Siegfried Thurnher
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

Review 5.  Autoimmune thrombocytopenic purpura.

Authors:  J B Bussel
Journal:  Hematol Oncol Clin North Am       Date:  1990-02       Impact factor: 3.722

6.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

7.  Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors--a retrospective single-center analysis.

Authors:  O Kress; H-J Wagner; M Wied; K J Klose; R Arnold; H Alfke
Journal:  Digestion       Date:  2003-10-31       Impact factor: 3.216

Review 8.  Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

Authors:  Thomas J Vogl; Nagy N N Naguib; Stefan Zangos; Katrin Eichler; Alborz Hedayati; Nour-Eldin A Nour-Eldin
Journal:  Eur J Radiol       Date:  2008-10-01       Impact factor: 3.528

9.  Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro.

Authors:  J G Kelton; D Meltzer; J Moore; A R Giles; W E Wilson; R Barr; J Hirsh; P B Neame; P J Powers; I Walker; F Bianchi; C J Carter
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

Review 10.  Embolization and chemoembolization therapy for neuroendocrine tumors.

Authors:  A P Venook
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645

View more
  1 in total

1.  Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia.

Authors:  Lin Zhou; Lin-Zhi Zhang; Jing-Yan Wang; Yong-Wu Li; Hai-Dong Hu; Xiao-Ming Peng; Yun Zhao; Xi-Ming Wang; Hui Xie; Chun-Zi Liu; Hua-Ming Wang
Journal:  Mol Clin Oncol       Date:  2017-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.